Navigation Links
Join Cato BioVentures and Cancer Advances at Biotech Showcase 2013 & J.P. Morgan 31st Annual Healthcare Conference
Date:1/7/2013

Durham, NC (PRWEB) January 07, 2013

Experts from Cato BioVentures and Cancer Advances are attending Biotech Showcase 2013 and J.P. Morgan 31st Annual Healthcare Conference this week in San Francisco. These two annual events bring together private and public investors and pharmaceutical executives from around the world to meet in one place for two of the healthcare industry's largest conferences.

Attending experts include: Daniel Pharand, C.P.A., C.A., Principal of Cato BioVentures and Chief Financial Officer of Cato Research as well as Chief Executive Officer and Chief Financial Officer of Cancer Advances; Jo Cato, Ph.D., Vice President of Cato BioVentures and Chief Operating Officer of Cato Research; and David Gee, Strategic Business Developer of Cato Research.

These experts, along with other Cato BioVentures and Cancer Advances representatives, will participate in Biotech Showcase 2013, attending one-on-one partnering meetings and the J.P. Morgan conference.

To set up a meeting with Cato BioVentures or Cancer Advances, please call 919-361-2286. For more information, you may visit:
http://www.cato.com/marketing/2013/2013-Biotech_CatoBioVentures.html

About Cato BioVentures:
Cato BioVentures is the venture capital affiliate of Cato Research, a global contract research and development organization (CRO). For over 20 years, Cato BioVentures and Cato Research have partnered with entrepreneurs, academic institutions, and a broad base of biotechnology and pharmaceutical companies to advance a robust portfolio of successful product development programs. Through strategic CRO service agreements with Cato Research, Cato BioVentures has invested its CRO Service Capital™ in innovative therapeutics, medical devices, and stem cell technologies that improve the pharmaceutical industry’s research and development productivity. If strategic outsourcing for development, regulatory, and clinical support is a core component of a company’s business plan, then Cato BioVenture’s investment model can make a positive difference in the company’s overall success. For more information about Cato BioVentures, call 919-361-2286 or visit http://www.catobioventures.com.

About Cancer Advances:
Cancer Advances is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio. Please visit our product page for more information on what is in development: http://www.canceradvancesinc.com/product.html

About Cato Research:
Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, North Carolina, Cato Research is a full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of approximately 300 and offices located in the United States, Europe, Canada, Israel, and South Africa, the Cato Research team consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their clients’ products to market with speed and cost effectiveness. For more information about Cato Research, visit http://www.cato.com.

# # #

Read the full story at http://www.prweb.com/releases/2013/1/prweb10292438.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
3. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
4. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
5. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
6. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
7. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):